Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670455 | 0.89 | BACE1 (0.35) | BACE1GRM5 | |
| SCHEMBL14670423 | 0.86 | PTGES (0.31) | BACE1 | |
| SCHEMBL3023334 | 0.85 | NR3C2 (0.38) | BACE1 | |
| SCHEMBL15062313 | 0.81 | GRM5 (0.33) | CYP3A4CYP2C9CYP2C19BACE1GRM5 | |
| SCHEMBL14670425 | 0.77 | BACE1 (0.31) | BACE1 | |
| SCHEMBL3011515 | 0.74 | NR3C2 (0.46) | CYP3A4BACE1 | |
| SCHEMBL12085058 | 0.74 | BACE1 (0.34) | BACE1GRM5 | |
| SCHEMBL14670424 | 0.73 | BRD4 (0.34) | — | |
| SCHEMBL15062299 | 0.72 | PTGES (0.33) | BACE1 | |
| SCHEMBL3016974 | 0.71 | NR3C2 (0.39) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | CYP3A4 604/4885CYP2C9 1005/4885CYP2C19 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.